Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $7 | $3 | $41 |
| % Growth | 87.7% | 126.1% | -92.1% | – |
| Cost of Goods Sold | $3 | $1 | $0 | $0 |
| Gross Profit | $11 | $6 | $3 | $41 |
| % Margin | 81.7% | 87.9% | 100% | 100% |
| R&D Expenses | $23 | $29 | $39 | $34 |
| G&A Expenses | $18 | $21 | $21 | $21 |
| SG&A Expenses | $18 | $23 | $21 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $1 | $0 | $16 | $0 |
| Operating Expenses | $41 | $52 | $77 | $56 |
| Operating Income | -$30 | -$46 | -$74 | -$15 |
| % Margin | -221.5% | -627.8% | -2,281.8% | -35.9% |
| Other Income/Exp. Net | $1 | -$1 | $3 | -$2 |
| Pre-Tax Income | -$30 | -$47 | -$70 | -$17 |
| Tax Expense | $1 | $1 | -$1 | $1 |
| Net Income | -$30 | -$48 | -$74 | -$18 |
| % Margin | -221.8% | -653.2% | -2,303.4% | -43.1% |
| EPS | -0.12 | -0.19 | -0.29 | -0.069 |
| % Growth | 36.8% | 34.5% | -320.3% | – |
| EPS Diluted | -0.12 | -0.19 | -0.29 | -0.069 |
| Weighted Avg Shares Out | 264 | 257 | 256 | 256 |
| Weighted Avg Shares Out Dil | 264 | 257 | 256 | 256 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $2 | $2 |
| Interest Expense | $1 | $2 | $2 | $1 |
| Depreciation & Amortization | $3 | $2 | $3 | $3 |
| EBITDA | -$26 | -$43 | -$68 | -$13 |
| % Margin | -192% | -585.6% | -2,109.7% | -31.4% |